DOCSLIB.ORG

Termin Translat Trna Utr Mutat Protein Signal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Termin Translat Trna Utr Mutat Protein Signal Drugs & Chemicals 1: Tumor Suppressor Protein p53 2: Heterogeneous-Nuclear Ribonucleo- (1029) proteins (14) activ apoptosi arf cell express function inactiv induc altern assai associ bind mdm2 mutat p53 p73 pathwai protein regul complex detect exon famili genom respons suppress suppressor tumor wild-typ interact intron isoform nuclear protein sensit site specif splice suggest variant 3: RNA, Transfer (110) 4: DNA Primers (1987) codon contain differ eukaryot gene initi amplifi analysi chain clone detect dna express mrna protein region ribosom rna fragment gene genotyp mutat pcr sequenc site speci suggest synthesi polymorph popul primer reaction region restrict sequenc speci termin translat trna utr 5: Saccharomyces cerevisiae Proteins 6: Apoptosis Regulatory Proteins (291) (733) activ apoptosi apoptosis-induc albican bud candida cerevisia complex encod apoptot bcl-2 caspas caspase-8 cell eukaryot fission function growth interact involv death fasl induc induct ligand methyl necrosi pathwai program sensit surviv trail mutant pomb protein requir saccharomyc strain suggest yeast 7: Plant Proteins (414) 8: Membrane Proteins (1608) access arabidopsi cultivar flower hybrid leaf leav apoptosi cell conserv domain express function gene human identifi inhibitor line maiz plant pollen rice root seed mammalian membran mice mous mutant seedl speci thaliana tomato transgen wheat mutat protein signal suggest transport 1 9: Tumor Suppressor Proteins (815) 10: 1-Phosphatidylinositol 3-Kinase activ arrest cell cycl cyclin damag delet dna (441) 3-kinas activ akt cell egf egfr express function gene methyl mutat p53 epiderm factor gefitinib inhibit inhibitor promot protein repair suppressor system growth kinas pathwai phosphoryl pi3k receptor tumor signal surviv tyrosin 11: Proteins (1227) 12: Enzyme Precursors (42) algorithm apoptosi avail cell data databas domain encod express function gene inform method mice mutat activ analysi cell differ evid express function increas kinas mechan phosphoryl protein network predict protein set structur provid role signal site specif structur suggest tyrosin 13: Caspase 1 (15) 14: Caspases (794) apoptosi associ cell control activ apoptosi apoptot bax bcl-2 caspas caspase-3 cell death induc induct death express famili gene inhibit inhibitor mechan pathwai proapoptot protein releas surviv trail increas induc level member mice mous mutant phenotyp rat respons role select 15: Cytochromes c (184) 16: Intracellular Signaling Peptides and Proteins (602) activ apoptosi apoptot bax bcl-2 caspas caspase-3 cell cytochrom death activ apoptosi cell death induc induct inhibitor mechan mitochondri mitochondria mtdna pathwai protein releas diseas express function gene induc interact kinas mechan mutat pathwai patient phosphoryl protein regul role signal 2 17: Frizzled Receptors (22) 18: Receptors, G-Protein-Coupled activ beta-catenin cell differ famili form format (175) identifi involv local mechan pathwai protein action activ agonist alpha antagonist beta cell express gamma gene glucocorticoid ligand mediat pathwai regul requir role sequenc signal receptor role signal stimul studi transduct wnt subunit 19: Macromolecular Substances (157) 20: Eye Proteins (215) cell conclusions cone degener develop activ assembl bind complex compon dna essenti form format function human examin express gene implant macular interact model process protein recruit requir site structur subunit methods mutat optic photoreceptor pigment protein retin retina studi visual 21: Drosophila Proteins (613) 22: Protein Kinase C (266) adult aphid conserv control differ activ c-jun cell erk increas induc inhibit drosophila fli fly function inhibitor jnk kinas mapk host insect larva larval mammalian melanogast mitogen-activ p38 pathwai mosquito pheromon speci suggest wing phosphoryl pkc protein regul signal stimul 23: DNA-Binding Proteins (3805) 24: Nerve Tissue Proteins (954) activ bind cell damag dna domain associ bind cell depress diseas disord express function gene genet express factor function gene identifi interact mechan mice motor mutat neuron progress protein studi mice mutat promot protein regul regulatori repair signal site transcript 3 25: Transcription Factors (3309) 26: Repressor Proteins (859) activ bind cell develop differenti element express activ cell chromatin control domain express factor function gene mutat pathwai factor function gene histon mutat pathwai promot regul regulatori repress role signal site transcript promot protein regul regulatori repress role signal transcript 27: DNA (2387) 28: Tumor Markers, Biological (1491) analysi cancer carcinoma clinic express allel analysi associ bind damag dna fragment gene genet genom genotyp mutat pcr factor gene lesion marker polymorph popul promot region repair replic sequenc outcom patient poor predict prognosi prognost specimen stage stain surviv tumor 29: Nitrates (54) 30: Organometallic Compounds (54) concentr demonstr differ effect group acid associ caus cell chang increas level model nitric oxid activ produc product rate reduc sampl studi suggest synthas combin complex compound water synthesi deriv effect group high increas model process select structur studi treatment 31: Lead (43) 32: Kinesin (65) caus dose effect expos cell centrosom chromosom exposur function genet group health increas irradi lead level method model develop divis express famili radiat respons sampl studi water function gene meiotic microtubul mitosi mitot protein requir respons segreg sequenc specif 4 spindl 33: Neutral Red (6) 34: Paclitaxel (309) advanc agent anticanc cancer assai caus cell concentr dai chemotherapi cisplatin combin cytotox detect determin dna effect evid exposur light method microm min rat drug effect median paclitaxel specif support test sensit patient phase regimen respons sensit surviv toxic treatment 35: Tubulin Modulators (5) 36: Tubulin (142) agent bind cancer data drug activ cell centrosom checkpoint estim exposur identifi effect chromosom cytokinesi divis inhibit larg method new reduc screen express increas local meiosi meiotic size small structur target therapi microtubul mitosi mitot protein requir segreg spindl studi 37: HLA Antigens (146) 38: Histocompatibility Antigens Class I (233) allel antigen associ class complex donor drb1 genet histocompat hla human leukocyt major allel antigen barrier class complex drb1 natur patient present transplant mhc molecul gap leukocyt type histocompat hla human iron junction major mhc molecul natur present specif type 39: Spectrin (22) 40: Factor IX (28) cell control decreas defici earli function adenoviru adult analysi deliveri develop differ effici express factor group human identifi increas gene growth human mechan molecular studi larg level local new number therapi transfer year observ protein rel sampl studi suggest vector 5 41: Hepatitis delta Antigens (3) 42: Calcium (528) affect analysi blot conserv detect dna activ atp bone ca2+ calcium cam cell express form format gene gener channel current function gate mammalian mutant protein region human intracellular ion potassium potenti receptor releas sodium subunit respons reveal sequenc vector western 43: Glycine (128) 44: Oxygen (281) acid activ analysi control diseas enzym function activ antioxid damag differ endotheli energi enzym free function increas level gene increas model mutant mutat patient polymorph posit residu site structur measur oxygen rate reactiv studi substitut oxid respons speci stress studi 45: Sulfatases (11) 46: Cysteine (166) detect develop chang cleavag cystein form function group human activ increas indic mutant mutat posit proteas protein enzym function gene genom residu role serin stabil structur high isol level low mutat product protein site site specif strain structur substrat tissu 47: Histones (546) 48: Histone Deacetylases (285) acetyl activ associ chromatin acetyl activ associ cbp chromatin coactiv deacetylas dna gene hdac coactiv deacetylas gene hdac histon histon mechan modif nucleosom mechan modif nucleosom p300 recruit regul p300 recruit regul remodel repress silenc remodel repress silenc transcript transcript 6 49: Sirtuins (40) 50: Lysine (199) acetyl activ chromatin cleavag degrad differ acetyl activ chromatin coactiv domain effect function gene histon increas combin deacetylas function hdac mutat proteas protein residu site histon mechan modif mutant specif structur transcript nucleosom recruit regul remodel repress role studi transcript 51: Silent Information Regulator Pro- 52: Phosphoglycerate Dehydrogenase teins, Saccharomyces cerevisiae (23) (1) acetyl activ assembl biosynthesi catalyt acetyl activ chromatin complex control deacetylas enhanc gene high chromatin complex compon conform crystal deacetylas enzym form histon level low modif mutat popul recruit regul suggest transcript yeast histon modif recruit structur substrat subunit transcript 53: NAD (47) 54: O-Acetyl-ADP-Ribose (2) activ biochem biosynthesi catalyt catalyz cell activ alter chromatin control dehydrogenas effect enzym chang conserv decreas function enzymat human metabol pathwai protein reaction complex enzym gene histon increas mutant peptid recombin reductas respons substrat treatment splice substrat variant wild-typ yeast 55: Mutagens (252) 56: RNA, Viral (502) assai assess carcinogen chemic damag dna dose antivir capsid genom hbv hcv hepat hiv hiv-1 host effect expos exposur frequenc human immunodefici infect infecti particl replic genotox increas indic induc mutagen potenti studi toxic worker rna viral virion viru virus 7 57: Fluorouracil (367) 58: Factor VIII (63) advanc agent cancer chemotherapi associ bleed
Load more

Recommended publications
  • Endogenous Reverse Transcriptase and Rnase H-Mediated Antiviral Mechanism in Embryonic Stem Cells
    www.nature.com/cr www.cell-research.com ARTICLE Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells Junyu Wu1, Chunyan Wu1, Fan Xing1, Liu Cao1, Weijie Zeng1, Liping Guo1, Ping Li1, Yongheng Zhong1, Hualian Jiang1, Manhui Luo1, Guang Shi2, Lang Bu1, Yanxi Ji1, Panpan Hou1, Hong Peng1, Junjiu Huang2, Chunmei Li1 and Deyin Guo 1 Nucleic acid-based systems play important roles in antiviral defense, including CRISPR/Cas that adopts RNA-guided DNA cleavage to prevent DNA phage infection and RNA interference (RNAi) that employs RNA-guided RNA cleavage to defend against RNA virus infection. Here, we report a novel type of nucleic acid-based antiviral system that exists in mouse embryonic stem cells (mESCs), which suppresses RNA virus infection by DNA-mediated RNA cleavage. We found that the viral RNA of encephalomyocarditis virus can be reverse transcribed into complementary DNA (vcDNA) by the reverse transcriptase (RTase) encoded by endogenous retrovirus-like elements in mESCs. The vcDNA is negative-sense single-stranded and forms DNA/RNA hybrid with viral RNA. The viral RNA in the heteroduplex is subsequently destroyed by cellular RNase H1, leading to robust suppression of viral growth. Furthermore, either inhibition of the RTase activity or depletion of endogenous RNase H1 results in the promotion of virus proliferation. Altogether, our results provide intriguing insights into the antiviral mechanism of mESCs and the antiviral function of endogenized retroviruses and cellular RNase H. Such a natural nucleic acid-based antiviral mechanism in mESCs is referred to as ERASE (endogenous RTase/RNase H-mediated antiviral system), which is an addition to the previously known nucleic acid-based antiviral mechanisms including CRISPR/Cas in bacteria and RNAi in plants and invertebrates.
    [Show full text]
  • Human Prion-Like Proteins and Their Relevance in Disease
    ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en Universitat Autònoma de Barcelona Departament de Bioquímica i Biologia Molecular Institut de Biotecnologia i Biomedicina HUMAN PRION-LIKE PROTEINS AND THEIR RELEVANCE IN DISEASE Doctoral thesis presented by Cristina Batlle Carreras for the degree of PhD in Biochemistry, Molecular Biology and Biomedicine from the Universitat Autònoma de Barcelona. The work described herein has been performed in the Department of Biochemistry and Molecular Biology and in the Institute of Biotechnology and Biomedicine, supervised by Prof. Salvador Ventura i Zamora. Cristina Batlle Carreras Prof. Salvador Ventura i Zamora Bellaterra, 2020 Protein Folding and Conformational Diseases Lab. This work was financed with the fellowship “Formación de Profesorado Universitario” by “Ministerio de Ciencia, Innovación y Universidades”. This work is licensed under a Creative Commons Attributions-NonCommercial-ShareAlike 4.0 (CC BY-NC- SA 4.0) International License. The extent of this license does not apply to the copyrighted publications and images reproduced with permission. (CC BY-NC-SA 4.0) Batlle, Cristina: Human prion-like proteins and their relevance in disease. Doctoral Thesis, Universitat Autònoma de Barcelona (2020) English summary ENGLISH SUMMARY Prion-like proteins have attracted significant attention in the last years.
    [Show full text]
  • Specific Principles of Genome-Wide RNA-Chromatin Interactions
    ARTICLE There are amendments to this paper https://doi.org/10.1038/s41467-020-14337-6 OPEN RADICL-seq identifies general and cell type–specific principles of genome-wide RNA-chromatin interactions Alessandro Bonetti 1,2,18*, Federico Agostini 3,18, Ana Maria Suzuki1,4, Kosuke Hashimoto1, Giovanni Pascarella1, Juliette Gimenez 5, Leonie Roos6,7, Alex J. Nash6,7, Marco Ghilotti1, Christopher J. F. Cameron8,9, Matthew Valentine 1, Yulia A. Medvedeva10,11,12, Shuhei Noguchi1, Eneritz Agirre 2, Kaori Kashi1, Samudyata2, Joachim Luginbühl1, Riccardo Cazzoli13, Saumya Agrawal1, Nicholas M. Luscombe 3,14,15, Mathieu Blanchette8, Takeya Kasukawa 1, Michiel de Hoon1, Erik Arner1, 1234567890():,; Boris Lenhard 6,7,16, Charles Plessy 1, Gonçalo Castelo-Branco 2, Valerio Orlando5,17* & Piero Carninci 1* Mammalian genomes encode tens of thousands of noncoding RNAs. Most noncoding tran- scripts exhibit nuclear localization and several have been shown to play a role in the reg- ulation of gene expression and chromatin remodeling. To investigate the function of such RNAs, methods to massively map the genomic interacting sites of multiple transcripts have been developed; however, these methods have some limitations. Here, we introduce RNA And DNA Interacting Complexes Ligated and sequenced (RADICL-seq), a technology that maps genome-wide RNA–chromatin interactions in intact nuclei. RADICL-seq is a proximity ligation-based methodology that reduces the bias for nascent transcription, while increasing genomic coverage and unique mapping rate efficiency compared with existing methods. RADICL-seq identifies distinct patterns of genome occupancy for different classes of tran- scripts as well as cell type–specific RNA-chromatin interactions, and highlights the role of transcription in the establishment of chromatin structure.
    [Show full text]
  • The Role of Protein Crystallography in Defining the Mechanisms of Biogenesis and Catalysis in Copper Amine Oxidase
    Int. J. Mol. Sci. 2012, 13, 5375-5405; doi:10.3390/ijms13055375 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review The Role of Protein Crystallography in Defining the Mechanisms of Biogenesis and Catalysis in Copper Amine Oxidase Valerie J. Klema and Carrie M. Wilmot * Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 321 Church St. SE, Minneapolis, MN 55455, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-612-624-2406; Fax: +1-612-624-5121. Received: 6 April 2012; in revised form: 22 April 2012 / Accepted: 26 April 2012 / Published: 3 May 2012 Abstract: Copper amine oxidases (CAOs) are a ubiquitous group of enzymes that catalyze the conversion of primary amines to aldehydes coupled to the reduction of O2 to H2O2. These enzymes utilize a wide range of substrates from methylamine to polypeptides. Changes in CAO activity are correlated with a variety of human diseases, including diabetes mellitus, Alzheimer’s disease, and inflammatory disorders. CAOs contain a cofactor, 2,4,5-trihydroxyphenylalanine quinone (TPQ), that is required for catalytic activity and synthesized through the post-translational modification of a tyrosine residue within the CAO polypeptide. TPQ generation is a self-processing event only requiring the addition of oxygen and Cu(II) to the apoCAO. Thus, the CAO active site supports two very different reactions: TPQ synthesis, and the two electron oxidation of primary amines. Crystal structures are available from bacterial through to human sources, and have given insight into substrate preference, stereospecificity, and structural changes during biogenesis and catalysis.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0155567 A1 Burk Et Al
    US 2014O155567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0155567 A1 Burk et al. (43) Pub. Date: Jun. 5, 2014 (54) MICROORGANISMS AND METHODS FOR (60) Provisional application No. 61/331,812, filed on May THE BIOSYNTHESIS OF BUTADENE 5, 2010. (71) Applicant: Genomatica, Inc., San Diego, CA (US) Publication Classification (72) Inventors: Mark J. Burk, San Diego, CA (US); (51) Int. Cl. Anthony P. Burgard, Bellefonte, PA CI2P 5/02 (2006.01) (US); Jun Sun, San Diego, CA (US); CSF 36/06 (2006.01) Robin E. Osterhout, San Diego, CA CD7C II/6 (2006.01) (US); Priti Pharkya, San Diego, CA (52) U.S. Cl. (US) CPC ................. CI2P5/026 (2013.01); C07C II/I6 (2013.01); C08F 136/06 (2013.01) (73) Assignee: Genomatica, Inc., San Diego, CA (US) USPC ... 526/335; 435/252.3:435/167; 435/254.2: (21) Appl. No.: 14/059,131 435/254.11: 435/252.33: 435/254.21:585/16 (22) Filed: Oct. 21, 2013 (57) ABSTRACT O O The invention provides non-naturally occurring microbial Related U.S. Application Data organisms having a butadiene pathway. The invention addi (63) Continuation of application No. 13/101,046, filed on tionally provides methods of using Such organisms to produce May 4, 2011, now Pat. No. 8,580,543. butadiene. Patent Application Publication Jun. 5, 2014 Sheet 1 of 4 US 2014/O155567 A1 ?ueudos!SMS |?un61– Patent Application Publication Jun. 5, 2014 Sheet 2 of 4 US 2014/O155567 A1 VOJ OO O Z?un61– Patent Application Publication US 2014/O155567 A1 {}}} Hººso Patent Application Publication Jun.
    [Show full text]
  • Enhanced Phosphorylation of High-Mobility-Group Proteins In
    Proc. Nati. Acad. Sci. USA Vol. 78, No. 4, pp. 2189-2193, April 1981 Biochemistry Enhanced phosphorylation of high-mobility-group proteins in nuclease-sensitive mononucleosomes from butyrate-treated HeLa cells (hyperphosphorylation/transcriptionally active chromatin/sodium butyrate) BEATRIZ LEVY-WILSON Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92717 Communicated by James F. Bonner, December 29, 1980 ABSTRACT The protein composition of nucleosome fractions MATERIALS AND METHODS differing in their sensitivity to micrococcal nuclease and derived from butyrate-treated or untreated HeLa cells has been com- Cell Cultures. HeLa cells, line S3, were grown in monolay- pared. Most of the high-mobility-group-14 (HMG-14) and HMG- ers, either in T-150 culture flasks or in roller bottles, at 370C 17 content of HeLa cell chromatin is associated with those nu- in minimal essential medium (Flow Laboratories, Rockville, cleosomes that are preferentially sensitive to micrococcal nu- MD) supplemented with 7% bovine calfserum (KC Biologicals) clease. Furthermore, electrophoresis of these two HMG proteins and penicillin (100 units/ml) and streptomycin (100 Ag/ml) from the transcriptionally active chromatin fraction MN, of bu- (Sigma). In experiments involving sodium butyrate, this com- tyrate-treated cells resolves them into a series ofbands. The mul- pound was added to the cultures at a final concentration of5 mM tiple band pattern of HMG-14 and -17 from butyrate-treated cells about 20 hr prior to harvesting of the cells. results from hyperphosphorylation rather than hyperacetylation. Preparation of Nuclei. HeLa cell nuclei were prepared as Phosphorylation of these two small nonhistone proteins may play described by Milcarek et al.
    [Show full text]
  • Supplementary Data for “Sequence and Annotation of the 369-Kb NY-2A and the 345-Kb AR158 Viruses That Infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Virology Papers Virology, Nebraska Center for 2-20-2007 Supplementary Data for “Sequence and annotation of the 369-kb NY-2A and the 345-kb AR158 viruses that infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L Lisa A. Fitzgerald University of Nebraska-Lincoln, [email protected] Michael V. Graves University of Massachusetts–Lowell, [email protected] Xiao Li University of Massachusetts–Lowell Tamara Feldblyum The Institute for Genomic Research, Rockville, MD Willaim C. Nierman The Institute for Genomic Research, Rockville, MD, [email protected] See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/virologypub Part of the Virology Commons Fitzgerald, Lisa A.; Graves, Michael V.; Li, Xiao; Feldblyum, Tamara; Nierman, Willaim C.; and Van Etten, James L., "Supplementary Data for “Sequence and annotation of the 369-kb NY-2A and the 345-kb AR158 viruses that infect Chlorella NC64A”: Appendix D: Gene Names C006R – C815L" (2007). Virology Papers. 10. https://digitalcommons.unl.edu/virologypub/10 This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors Lisa A. Fitzgerald, Michael V. Graves, Xiao Li, Tamara Feldblyum, Willaim C. Nierman, and James L. Van Etten This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/ virologypub/10 Main article published in Virology 358:2 (February 20, 2007), pp.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Metabolism Of
    PHARMACOKINETICS, PHARMACODYNAMICS AND METABOLISM OF GTI-2040, A PHOSPHOROTHIOATE OLIGONUCLEOTIDE TARGETING R2 SUBUNIT OF RIBONUCLEOTIDE REDUCTASE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Xiaohui Wei, M.S. * * * * * * The Ohio State University 2006 Approved by Dissertation Committee: Dr. Kenneth K. Chan, Adviser Adviser Dr. Guido Marcucci, Co-adviser Graduate Program in Pharmacy Dr. Thomas D. Schmittgen Dr. Robert J. Lee Co-Adviser Graduate Program in Pharmacy ABSTRACT Over the last several decades, antisense therapy has been developed into a promising gene-targeted strategy to specifically inhibit the gene expression. Ribonucleotide reductase (RNR), composing of subunits R1 and R2, is an important enzyme involved in the synthesis of all of the precursors used in DNA replication. Over- expression of R2 has been found in almost every type of cancer studied. GTI-2040 is a 20-mer phosphorothioate oligonucleotide targeting the coding region in mRNA of the R2 component of human RNR. In this project, clinical pharamcokinetics (PK), pharmacodynamics (PD) and metabolism of this novel therapeutics were investigated in patients with acute myeloid leukemia (AML). A picomolar specific hybridization-ligation ELISA method has been developed and validated for quantification of GTI-2040. GTI-2040 and neophectin complex was found to enhance drug cellular uptake and exhibited sequence- and dose-dependent down-regulation of R2 mRNA and protein in K562 cells. Robust intracellular concentrations (ICs) of GTI-2040 were achieved in peripheral blood mononuclear cells (PBMC) and bone marrow (BM) cells from treated AML patients. GTI-2040 concentrations in the nucleus of BM cells were found to correlate with the R2 mRNA down-regulation and disease response.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]